中文名：CDKI-73
英文名：CDKI-73
純度：Moligand?，≥95%
貨號：C413829
Cas號：1421693-22-2
存儲溫度：-20°C儲存,充氬
運輸條件：超低溫運輸
產(chǎn)品介紹：
Information
CDKI-73 (LS-007) is a potentCDKinhibitor in vitro with IC50 of 8.17 nM, 3.27 nM, 8.18 nM, and 5.78 nM for CDK1, CDK2, CDK4, and CDK9, respectively. CDKI-73 induces apoptosis in cancer cells. CDKI-73 is an orally bioavailable and highly efficaciousCDK9inhibitor against acute myeloid leukemia.
Targets
CDK2 (Cell-free assay); CDK9 (Cell-free assay); CDK1 (Cell-free assay); CDK4 (Cell-free assay) 3.27 nM; 5.78 nM; 8.17 nM; 8.18 nM
In vitro
CDKI-73 induces cancer cells undergoing apoptosis through transcriptional downregulation of anti-apoptotic proteins Bcl-2, Mcl-1 and XIAP by majorly targeting CDK9. Contrastively, it is relatively low toxic to the bone marrow cells of healthy donors.
In vivo
CDKI-73 is orally bioavailable, highly efficacious against MLL-AML MV4–11 xenografts and downregulates anti-apoptotic proteins by targeting CDK9 in vivo.
Cell Research(from reference)
Cell lines：Leukemia cell lines (MOLM13, MV4-11, THP-1, etc.)?
Concentrations：0.05 μM, 0.1 μM, 0.25 μM, 0.5 μM?
Incubation Time：1 h, 4 h, 12 h, 24 h, 48 h?
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對應頁面：https://www.aladdin-e.com/zh_cn/C413829.html
關(guān)鍵字： GAIOPWBQKZMUNO-UHFFFAOYSA-N ; MS-26626 ; 3-((5-fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)benzenesulfonamide ; A925431
上海阿拉丁生化科技股份有限公司是A股上市公司（（股票代碼：688179），專注于科研試劑的研發(fā)、生產(chǎn)和銷售，已陸續(xù)建立多個工廠和研發(fā)中心。作為領軍企業(yè)，阿拉丁始終堅持質(zhì)量第一，連續(xù)13年被評為“最受歡迎試劑品牌”。
阿拉丁目前常備庫存試劑產(chǎn)品品種超過7萬種，SKU總數(shù)超過46萬，產(chǎn)品線涵蓋了化學試劑、生化試劑、藥靶配體、蛋白質(zhì)和抗體等多個領域，是國內(nèi)少數(shù)化學試劑到生物試劑全面發(fā)展的國產(chǎn)試劑品牌，產(chǎn)品同步發(fā)布在我們國內(nèi)外電商平臺。